2017 Annual Meeting | C214 - Multiple Sclerosis Overview II: Clinical Advances

Date Thursday 04/27/17

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Scott D. Newsome, DO, FAAN

Topic(s)

Learning Objectives Participants should feel more confident in prescribing and monitoring multiple sclerosis (MS) disease-modifying therapies (DMTs) as it relates to their efficacy and safety profiles along with develop a better understanding of key considerations in clinical practice. Participants will also become familiar with late-stage DMTs that have a strong potential of getting approved for use in MS. Participants should also be able to recognize what factors put an MS patient at risk for long-term disability and when to consider switching therapies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
03:30 PM - 04:30 PM	Speaker	The Expanding Armamentarium of Multiple Sclerosis Therapeutics Scott D. Newsome, DO, FAAN
04:30 PM - 05:30 PM	Speaker	Case-based Considerations in Clinical Practice for Multiple Sclerosis Myla D. Goldman, MD, MSc, FAAN

Faculty Disclosures
Myla D. Goldman, MD, MSc, FAAN	Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Seronon. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen, IDEC. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentec. Dr. Goldman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ADAMAS. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharmceuticals. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich Biosciences. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainstorm Cell Therapeutics Ltd., .
Scott D. Newsome, DO, FAAN	Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from The Stiff Person Syndrome Research Foundation. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.

��ɫ��

��ɫ��